<DOC>
	<DOCNO>NCT02042664</DOCNO>
	<brief_summary>Glucagon-like peptide-1 ( GLP-1 ) receptor agonist new treatment type 2 diabetes , low blood glucose level ( enhancement glucose-dependent insulin secretion suppression excess glucagon secretion ) reduce weight induce satiety slow gastric emptying . Beneficial effect GLP-1 GLP-1 receptor ( GLP-1R ) agonists cardiovascular function suggest . They improve biomarkers CV risk , decrease systolic blood pressure , improve endothelial function beneficial effect myocardium . Nevertheless , study analyse effect GLP1 treatment myocardial function type 2 obese diabetic . Myocardial steatosis independent predictor diastolic dysfunction type 2 diabetes mellitus . It recently show 16 week caloric restriction obese patient diabetes decrease myocardial triglyceride content improve myocardial function ( cardiac output , normalized stroke volume , LV mass normalized end diastolic volume ) , diastolic function . However , study evaluate impact Glucagon-like peptide-1 ( GLP-1 ) receptor agonist obese diabetic myocardial TG content . Recent study suggest increased epicardial adipose tissue ( EAT ) could important risk factor cardiac disease . We others already evidence correlation volume epicardial adipose tissue presence severity coronaropathy . The impact weight loss volume EAT characteristic EAT mostly unknown .</brief_summary>
	<brief_title>Effect GLP-1 Receptor ( GLP-1R ) Agonists Cardiac Function Epicardial Adipose Tissue ( EAT ) Volume Myocardial TG Content Obese Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Exenatide</mesh_term>
	<criteria>Patients type 2 diabetes accord WHO criteria Age &gt; 18 year BMI â‰¥ 30 kg/m2 HbA1c &gt; 7 % &lt; 10 % Processing ADO ( Metformin Glimepiride ) Effective contraception ( woman ) Signed informed consent patient inclusion protocol Ongoing pregnancy become pregnant within six month study protocol Breastfeeding Recent weight loss ( &gt; 5 % total weight ) Treatments change distribution adipose tissue corticosteroid glitazones Acute coronary syndrome unstable angina last three month Contraindications cardiac MRI ( mechanical heart valve , pacemaker , metallic intraocular foreign body , claustrophobia ) Contraindication cold test : Raynaud 's syndrome Contraindication exenatide : Neoplasia active untreated remission le 5 year ( except basal cell carcinoma situ cervical prostate ) Contraindication ADO ( depend specific product ) combination exenatide . History kidney transplant dialysis plasmatique creatinine &gt; 1.5 mg / dL men &gt; 1.2 mg / dL woman Digestive disease , include gastroparesis plasma triglyceride &gt; 1000 mg / dL History pancreatitis confirm biologically contraindication hypersensitivity Exenatide one social coverage composantsAbsence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>